Lilly's arzoxifene superior to Evista in osteoporosis
This article was originally published in Scrip
Executive Summary
Lilly has demonstrated that its investigational selective oestrogen receptor modulator (SERM) arzoxifene is superior to its older SERM Evista (raloxifene hydrochloride) in increasing bone mineral density (BMD) in postmenopausal women with osteoporosis in a Phase III study.